SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

CIANCETTA, Antonella
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.373
EU - Europa 2.963
AS - Asia 2.321
SA - Sud America 493
Continente sconosciuto - Info sul continente non disponibili 179
AF - Africa 68
OC - Oceania 8
Totale 11.405
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.158
FI - Finlandia 1.910
SG - Singapore 914
CN - Cina 463
IT - Italia 423
BR - Brasile 381
VN - Vietnam 284
HK - Hong Kong 230
DE - Germania 110
GB - Regno Unito 102
CA - Canada 96
FR - Francia 91
BD - Bangladesh 83
RU - Federazione Russa 66
TR - Turchia 61
JP - Giappone 59
UA - Ucraina 58
IN - India 57
PL - Polonia 56
SE - Svezia 55
AR - Argentina 41
MX - Messico 36
ID - Indonesia 29
ZA - Sudafrica 28
NL - Olanda 24
EC - Ecuador 22
IQ - Iraq 22
PH - Filippine 20
CO - Colombia 16
HN - Honduras 15
CR - Costa Rica 14
UZ - Uzbekistan 14
PK - Pakistan 13
ES - Italia 12
AT - Austria 11
JM - Giamaica 11
PR - Porto Rico 9
TN - Tunisia 9
AE - Emirati Arabi Uniti 8
BE - Belgio 8
CZ - Repubblica Ceca 8
MY - Malesia 8
TT - Trinidad e Tobago 8
VE - Venezuela 8
CW - ???statistics.table.value.countryCode.CW??? 7
GP - Guadalupe 7
IL - Israele 7
LT - Lituania 7
AU - Australia 6
KE - Kenya 6
NI - Nicaragua 6
PY - Paraguay 6
SV - El Salvador 6
BO - Bolivia 5
CL - Cile 5
KR - Corea 5
UY - Uruguay 5
CH - Svizzera 4
DZ - Algeria 4
EG - Egitto 4
JO - Giordania 4
KZ - Kazakistan 4
MA - Marocco 4
PT - Portogallo 4
SA - Arabia Saudita 4
TW - Taiwan 4
AZ - Azerbaigian 3
CI - Costa d'Avorio 3
GT - Guatemala 3
PE - Perù 3
RS - Serbia 3
SY - Repubblica araba siriana 3
BY - Bielorussia 2
ET - Etiopia 2
GA - Gabon 2
IE - Irlanda 2
KH - Cambogia 2
KW - Kuwait 2
LB - Libano 2
MN - Mongolia 2
NP - Nepal 2
OM - Oman 2
PA - Panama 2
PS - Palestinian Territory 2
SC - Seychelles 2
AL - Albania 1
AM - Armenia 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
CV - Capo Verde 1
CY - Cipro 1
DK - Danimarca 1
EU - Europa 1
GE - Georgia 1
GF - Guiana Francese 1
GR - Grecia 1
HU - Ungheria 1
IR - Iran 1
KY - Cayman, isole 1
Totale 11.224
Salva come PNG Salva come JPEG
Città #
Helsinki 1.886
Dallas 1.033
Ashburn 733
Singapore 509
San Jose 456
Council Bluffs 255
Santa Clara 254
Hong Kong 222
Beijing 195
Chandler 139
Fairfield 138
Los Angeles 119
Ferrara 111
Ho Chi Minh City 103
Houston 101
Ann Arbor 93
Woodbridge 85
New York 77
Hanoi 60
Tokyo 58
Jacksonville 57
Seattle 54
Warsaw 53
Wilmington 52
Princeton 47
Cambridge 46
Lauterbourg 46
Buffalo 40
São Paulo 37
Munich 33
Bologna 32
Chicago 28
Milan 28
Izmir 25
Orem 25
Phoenix 24
Shanghai 24
Toronto 24
Brooklyn 22
Chennai 21
Jakarta 21
London 21
Rome 21
Washington 20
North Bergen 19
Montreal 18
San Diego 18
The Dalles 18
Atlanta 17
Mexico City 17
Nuremberg 17
Da Nang 16
Johannesburg 15
Stockholm 14
Curitiba 13
Denver 13
Frankfurt am Main 13
Nanjing 13
Tashkent 13
Turku 13
Manchester 12
Baghdad 11
Boardman 11
Boston 11
Redondo Beach 11
San Francisco 11
Changsha 10
Poplar 10
San José 10
Amsterdam 9
Falls Church 9
Quito 9
Brasília 8
Brno 8
Calgary 8
Irvine 8
Rio de Janeiro 8
Bari 7
Buenos Aires 7
Can Tho 7
Haiphong 7
Hefei 7
Hải Dương 7
Las Vegas 7
Salvador 7
Willemstad 7
Belo Horizonte 6
Brussels 6
Charlotte 6
Dhaka 6
Figino 6
Kingston 6
Lahore 6
Managua 6
Manila 6
Venice 6
Biên Hòa 5
City of London 5
Columbus 5
Florence 5
Totale 7.982
Salva come PNG Salva come JPEG
Nome #
[1,2,4]triazolo[1,5-c]pyrimidines as A(3) adenosine receptor antagonists 2.770
A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy 353
2-Arylpyrazolo[4,3-d]pyrimidin-7-amino derivatives as new potent and selective human A3 adenosine receptor antagonists. Molecular modeling studies and pharmacological evaluation 300
5,7-Disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazines as pharmacological tools to explore the antagonist selectivity profiles toward adenosine receptors 289
Novel Aryl Sulfonamide Derivatives as NLRP3 Inflammasome Inhibitors for the Potential Treatment of Cancer 244
Structural refinement of pyrazolo[4,3-d]pyrimidine derivatives to obtain highly potent and selective antagonists for the human A3 adenosine receptor 244
7-Amino-2-phenylpyrazolo[4,3-d]pyrimidine derivatives: Structural investigations at the 5-position to target human A(1) and A(2A) adenosine receptors. Molecular modeling and pharmacological studies 221
Structure activity relationship of 2-arylalkynyl-adenine derivatives as human A3 adenosine receptor antagonists 210
Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines and Structurally Simplified Analogs. Chemistry and SAR Profile as Adenosine Receptor Antagonists 208
Design and synthesis of 1,4,8-triazaspiro[4.5]decan-2-one derivatives as novel mitochondrial permeability transition pore inhibitors 200
The influence of the 1-(3-Trifluoromethyl-Benzyl)-1H-Pyrazole-4-yl moiety on the adenosine receptors affinity profile of pyrazolo[4,3-e][1,2,4]Triazolo[1,5-c] pyrimidine derivatives 199
A 2a adenosine receptor: Structures, modeling, and medicinal chemistry 194
A3 adenosine receptor activation mechanisms: molecular dynamics analysis of inactive, active, and fully active states 178
A Multi-Angle Approach to Predict Peptide-GPCR Complexes: The N/OFQ-NOP System as a Successful AlphaFold Application Case Study 173
Near-Complete Response to Osimertinib for Advanced Non-Small-Cell Lung Cancer in a Pretreated Patient Bearing Rare Compound Exon 20 Mutation (S768I + V774M): A Case Report 171
A QM/MM study of the binding of RAPTA ligands to cathepsin B 170
Probing non-peptide agonists binding at the human nociceptin/orphanin FQ receptor: a molecular modelling study 164
Bridging molecular docking to membrane molecular dynamics to investigate GPCR-ligand recognition: The human A2A adenosine receptor as a key study 151
Activation of carboplatin by carbonate: A theoretical investigation 131
P3.12.20 VAF of EGFR Mutations in Relation to Early Tumor Shrinkage or Deepness of Response During Osimertinib in NSCLC Patients 130
Aquaporin inhibition by gold(III) compounds: New insights 128
DockBench: An Integrated Informatic Platform Bridging the Gap between the Robust Validation of Docking Protocols and Virtual Screening Simulations 127
Revisiting a receptor-based pharmacophore hypothesis for human A(2A) adenosine receptor antagonists 126
Sensitivity of Binding Free Energy Calculations to Initial Protein Crystal Structure 125
Activation of carboplatin by chloride ions: a theoretical investigation 125
Deciphering the Complexity of Ligand-Protein Recognition Pathways Using Supervised Molecular Dynamics (SuMD) Simulations 123
Understanding allosteric interactions in G protein-coupled receptors using Supervised Molecular Dynamics: A prototype study analysing the human A3 adenosine receptor positive allosteric modulator LUF6000 122
New Trends in Inspecting GPCR-ligand Recognition Process: the Contribution of the Molecular Modeling Section (MMS) at the University of Padova 119
Probe Confined Dynamic Mapping for G Protein-Coupled Receptor Allosteric Site Prediction 119
Enhancing Ligand and Protein Sampling Using Sequential Monte Carlo 119
null 118
Conjugates between minor groove binders and Zn(II)-tach complexes: Synthesis, characterization, and interaction with plasmid DNA 118
Structure-Guided Modification of Heterocyclic Antagonists of the P2Y 14 Receptor 114
Alternative quality assessment strategy to compare performances of GPCR-ligand docking protocols: the human adenosine A(2A) receptor as a case study 114
Bitopic fluorescent antagonists of the A2A adenosine receptor based on pyrazolo[4,3-: E] [1,2,4]triazolo[1,5- c] pyrimidin-5-amine functionalized congeners 113
Advances in Computational Techniques to Study GPCR-Ligand Recognition 113
Supramolecular delivery systems for polyphenols: A green approach to predict in vivo permeability through an in vitro setup 112
Hidden GPCR structural transitions addressed by multiple walker supervised molecular dynamics (mwSuMD) 109
Pyrimidine nucleotides containing a (S)-methanocarba ring as P2Y6 receptor agonists 107
Rationalization of the inhibition activity of structurally related organometallic compounds against the drug target cathepsin B by DFT 101
Structure-Based Design of 3-(4-Aryl-1H-1,2,3-Triazol-1-yl)-Biphenyl Derivatives as P2Y14 Receptor Antagonists 101
Design and in Vivo Characterization of A 1 Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series 101
Targeting Aquaporin Function: Potent Inhibition of Aquaglyceroporin-3 by a Gold-Based Compound 98
Repurposing of a nucleoside scaffold from adenosine receptor agonists to opioid receptor antagonists 98
Advances in GPCR modeling evaluated by the GPCR Dock 2013 assessment: Meeting new challenges 96
Demystifying P2Y1 Receptor Ligand Recognition through Docking and Molecular Dynamics Analyses 96
Enhancing torsional sampling using fully adaptive simulated tempering 94
Synthesis and Spectroscopic Characterisation of a Heterodinuclear Iron(III)-Copper(II) Complex Based on an Asymmetric Dinucleating Ligand System 93
Purine (N)-Methanocarba Nucleoside Derivatives Lacking an Exocyclic Amine as Selective A3 Adenosine Receptor Agonists 93
Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists 92
Breakthrough in GPCR Crystallography and Its Impact on Computer-Aided Drug Design 91
Journal of Medicinal Chemistry Collection: Drug Discovery in Italy 91
null 90
Implementing the “Best Template Searching” tool into Adenosiland platform 90
South (S)- and north (N)-methanocarba-7-deazaadenosine analogues as inhibitors of human adenosine kinase 90
Perturbation of fluid dynamics properties of water molecules during G protein-coupled receptor-ligand recognition: the human A2A adenosine receptor as a key study 88
Exploring the recognition pathway at the human A2A adenosine receptor of the endogenous agonist adenosine using supervised molecular dynamics simulations 85
Structural probing and molecular modeling of the A3 adenosine receptor: A focus on agonist binding 80
Influence of key amino acid mutation on the active site structure and on folding in acetyl-CoA synthase: A theoretical perspective 72
Polypharmacology of conformationally locked methanocarba nucleosides 69
In silico 3D modeling of binding activities 68
P2Y14 Receptor 67
HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS 63
Protein–Ligand Docking: Virtual Screening and Applications to Drug Discovery 62
The Effects of Variant Allele Frequency for EGFR Mutation on Early Tumor Shrinkage and Deepness of Response to Osimertinib in Patients with Metastatic Non-Small Cell Lung Cancer: An Exploratory Analysis 60
The path to the G protein-coupled receptor structural landscape: Major milestones and future directions 60
Inspecting receptor-ligand interaction using molecular dynamics simulations: new insights from Adenosiland 59
Not Quite Folded: Challenges in Predicting the hNPS‐hNPSR‐Ile107 Complex With AlphaFold2 Multimer 34
Design of New Potent, Selective, and Long-Acting NOP Receptor Agonists through Multiple Sequential d-Amino Acid Substitutions of [Arg14 Lys15]N/OFQ(1-15)-NH2 33
Fully Automatable Relative Binding Free Energy Calculations with Enhanced Sampling Using FAST/MBAR 19
Mapping the N/OFQ(1−13)-NH2 Address Domain to Identify G Protein-Biased NOP Receptor Agonists 12
The Natural Mutation Arg221aTrp in Human α-Thrombin Abrogates Physiological Na+ Binding and Preferentially Hinders the Protease Anticoagulant Functions 8
Totale 11.405
Salva come PNG Salva come JPEG
Categoria #
all - tutte 50.888
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.535
Totale 53.423
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022242 0 0 0 0 16 5 18 61 20 7 13 102
2022/2023313 51 22 24 21 40 26 8 44 47 9 13 8
2023/2024271 16 25 27 12 28 48 14 24 7 4 4 62
2024/20251.244 19 21 98 23 137 100 38 64 229 172 183 160
2025/20266.889 394 383 1.139 452 621 203 508 237 2.212 454 174 112
2026/20271.525 134 413 420 469 89 0 0 0 0 0 0 0
Totale 11.405